BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives10.6.2026 14:30:00 CEST | Press release
Former coach to Andre Agassi joins ASE to support the Company's Agassi Intelligence platform, premium content initiatives and global growth strategy LAS VEGAS, NV / ACCESS Newswire / June 10, 2026 / Agassi Sports Entertainment Corp. (OTCID:AASP) ("ASE" or the "Company"), a sports, media, and technology platform focused on the global racket sports ecosystem and built around the iconic brands of Andre Agassi and Stefanie Graf, today announced that it has entered into a name and likeness license agreement with renowned tennis coach Darren Cahill. As a member of the team, Cahill will collaborate with ASE across a range of strategic initiatives, including the Company's previously announced Agassi Intelligence technology platform being developed in partnership with IBM, original content creation, media opportunities and other global growth initiatives designed to expand access to world-class coaching and deepen fan engagement across racket sports. Cahill, a former professional player and one
Leggett & Platt Automotive Launches New Brand Identity: Leggett Dynamics10.6.2026 12:50:00 CEST | Press release
ACCELERATES INNOVATION & GROWTH IN COMFORT, MOTION & SOFTWARE INTEGRATED SYSTEMS DETROIT, MI / ACCESS Newswire / June 10, 2026 / Leggett & Platt Automotive today announced the launch of its new brand identity, "Leggett Dynamics", and tagline "eMotion & Comfort for everyone, everywhere, every day" signaling a strategic shift to accelerate innovation and growth in comfort and motion systems for automotive, adjacent and diversified markets. Megatrend & Consumer Shifts "Leggett Dynamics creates experiences where comfort and motion feel effortless, intelligent, personalized and instinctive across all aspects of life. This positions us well in the market in terms of megatrends as well as anticipating and proactively innovating for future expectations," said Marinela Cirstea, President of Leggett Dynamics. According to Cirstea, comfort and motion are at the epicenter of converging megatrends and shifting consumers' priorities toward personalized experiences, health and wellness, plus instant
Camino Intercepts High-Grade Copper With 76.2m at 0.88% Cu Including 16.25m at 2.67% Cu and 6.82g/t Ag at Costa de Cobre in Peru; All Five Reported Drill Holes Intersect Strong Copper Mineralization10.6.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the exploration results from Phase 2 of the recent drilling campaign at its Costa de Cobre project ("Costa de Cobre" or the "Project" (formerly known as "Los Chapitos"(1)) in Peru. Camino completed five drill holes along the Diva trend corridor, where drilling activities focused on the Adriana target with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. The maximum drill hole depth was 260 metres and all five drill holes intercepted strong copper mineralization and spanned a strike length of approximately 400 metres. Key highlights of recent Costa de Cobre drill holes: Adriana: DCH-131: 69.8 m @ 0.47% Cu & 4.17 g/t Ag, including 32.0 m @ 0.75% Cu & 6.50 g/t Ag, and 9.75m @ 1.25% Cu & 6.46 g/t Ag, including 3.90 m @ 2.99% Cu & 15.63 g/t Ag Adrian
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom